Crisaborole Production Cost Reports

The report provides a detailed analysis essential for establishing a Crisaborole manufacturing plant. It encompasses all critical aspects necessary for Crisaborole production, including the cost of Crisaborole production, Crisaborole plant cost, Crisaborole production costs, and the overall Crisaborole manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Crisaborole production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Crisaborole is an FDA-approved drug that is widely known for its anti-inflammatory properties. It is widely used for the treatment of mild to moderate atopic dermatitis (AD) in patients two years and older. Moreover, it also finds its application as a topical ointment to treat and reduce inflammation and itching in both adults and children. Additionally, it is also used as a non-steroidal anti-inflammatory drug (NSAID) for alleviating symptoms of various skin inflammation.

The demand for Crisaborole is predominantly driven due to its key role as a steroid-free topical treatment for atopic dermatitis (AD) or eczema in adults and pediatric patients, which significantly boosts its demand in the pharmaceutical industry. Moreover, its usage for the treatment of various inflammatory skin conditions, such as redness, rashes, and itchiness, further accentuates its demand in the medical and healthcare industries. Additionally, factors, including the availability of raw materials (4-Hydroxy-3-bromobenzaldehyde, etc.), pricing, its application as topical treatment, compliance with healthcare regulations, scientific advancements, and quality standards, greatly influence industrial Crisaborole procurement globally.

Raw Material for Crisaborole Production

According to the Crisaborole manufacturing plant project report, the major raw material for Crisaborole production includes 4-Hydroxy-3-bromobenzaldehyde.

Manufacturing Process of Crisaborole

The extensive Crisaborole production cost report consists of the following industrial manufacturing process:

1. Production via Chemical Synthesis: This method of production is initiated by subjecting bromobenzaldehyde (4-Hydroxy-3-bromobenzaldehyde) to warm ethylene glycol in the presence of catalytic p-toluenesulfonic acid to form the corresponding acetal. Further, the obtained compound (acetal) undergoes nucleophilic aromatic substitution on reaction with fluorobenzonitrile to obtain diaryl ether. Then, the obtained diaryl ether undergoes a reduction in the presence of sodium borohydride, followed by protection with THP to form a bromobenzene intermediate. Then, the obtained product is subjected to lithium-halogen exchange, followed by a reaction with triisopropyl borate and acidification, which results in the formation of crisaborole as the final product.

Crisaborole belongs to the family of benzoxaboroles. The molecular formula of the compound is C14H10BN03, and its molar mass is 251.05 g/mol. The compound is an aromatic ether that serves as a non-steroidal anti-inflammatory drug. Moreover, the IUPAC name of the compound is 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile. The boiling point of the compound is 425.9°C, and its melting point is >130°C. The density of the compound is 1.33g/cm3, and it is generally stored at room temperature. Additionally, the compound is hygroscopic, white to beige powder that is slightly soluble in DMSO and Menthol. This drug is sold under the trade name EUCRISA and is only meant for topical use.